KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Moderna (MRNA) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Moderna (MRNA) over the last 10 years, with Q3 2025 value amounting to -$4.5 billion.

  • Moderna's Enterprise Value rose 3441.1% to -$4.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.5 billion, marking a year-over-year increase of 3441.1%. This contributed to the annual value of -$7.0 billion for FY2024, which is 1835.19% up from last year.
  • According to the latest figures from Q3 2025, Moderna's Enterprise Value is -$4.5 billion, which was up 3441.1% from -$5.1 billion recorded in Q2 2025.
  • Moderna's Enterprise Value's 5-year high stood at -$4.5 billion during Q3 2025, with a 5-year trough of -$10.7 billion in Q4 2021.
  • For the 5-year period, Moderna's Enterprise Value averaged around -$8.0 billion, with its median value being -$8.3 billion (2022).
  • As far as peak fluctuations go, Moderna's Enterprise Value plummeted by 53506.74% in 2021, and later soared by 3955.0% in 2025.
  • Moderna's Enterprise Value (Quarter) stood at -$10.7 billion in 2021, then grew by 7.69% to -$9.9 billion in 2022, then rose by 13.11% to -$8.6 billion in 2023, then grew by 18.35% to -$7.0 billion in 2024, then surged by 35.89% to -$4.5 billion in 2025.
  • Its Enterprise Value stands at -$4.5 billion for Q3 2025, versus -$5.1 billion for Q2 2025 and -$6.0 billion for Q1 2025.